OlaparibDrug-induced interstitial lung disease: 3 case reports

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2023年 / 1972卷 / 1期

关键词：

D O I：

10.1007/s40278-023-45665-2

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：284 / 284

相关论文

共 50 条

[1] OlaparibDrug-induced pseudoporphyria: case report
Reactions Weekly, 2023, 1973 (1) : 232 - 232
[2] OlaparibDrug-induced liver injury : case report
Reactions Weekly, 2024, 2017 (1) : 399 - 399
[3] OlaparibDrug induced interstital lung disease: case report
Reactions Weekly, 2024, 2037 (1) : 338 - 338
[4] Everolimus/temsirolimusDrug-induced interstitial lung disease: 3 case reports
Reactions Weekly, 2015, 1569 (1) : 107 - 107
[5] Gemcitabine/pembrolizumab/pemetrexedDrug‑induced interstitial lung disease: 3 case reports
Reactions Weekly, 2022, 1922 (1) : 286 - 286
[6] AfatinibDiarrhoea, interstitial lung disease and paronychia: 3 case reports
Reactions Weekly, 2021, 1837 (1) : 30 - 30
[7] Nivolumab/osimertinibHepatotoxicity and interstitial lung disease: 3 case reports
Reactions Weekly, 2017, 1668 (1) : 309 - 309
[8] AntineoplasticsDrug-induced interstitial lung disease: 6 case reports
Reactions Weekly, 2021, 1871 (1) : 50 - 50
[9] Rituximab-induced interstitial lung disease: five case reports
Naqibullah, Matiuallah
Shaker, Saher B.
Bach, Karen S.
Bendstrup, Elisabeth
EUROPEAN CLINICAL RESPIRATORY JOURNAL, 2015, 2 (01):
[10] Docetaxel/nivolumab/ramucirumabPsoriasis and interstitial lung disease: 3 case reports
Reactions Weekly, 2020, 1810 (1) : 95 - 95

← 1 2 3 4 5 →